Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Dynavax Technologies Corp. (NASDAQ:DVAX) was off $0.13 to $3.54 last week after EMA accepted for review an MAA for Heplisav to prevent HBV infection caused by all known subtypes in adults ages 18-70 years and in patients with chronic kidney disease. Heplisav is under FDA review to prevent HBV infection in adults ages 18-70, with a Feb. 24 PDUFA date.
NPS Pharmaceuticals Inc. (NASDAQ:NPSP) gained $0.06 to $7.91 last week after announcing FDA's Gastrointestinal Drugs Advisory Committee will meet on Oct. 16 to discuss an NDA for Gattex teduglutide to treat short bowel syndrome. The PDUFA date is Dec. 30.
Pharmacyclics Inc. (NASDAQ:PCYC) gained